Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

LISCure Biosciences

Request full access

Develops bacteria-mediated immunotherapeutic drugs

Seoul, South KoreaFounded 2018Biotech & Life Sciences

About LISCure Biosciences

LISCure Biosciences is a biotechnology company specializing in the development of live biotherapeutics and immunotherapeutic drugs. The company focuses on creating bacteria-mediated immunotherapies that can be used alone or in combination with other treatments to address major health conditions such as tumors, degenerative neurological diseases, autoimmune diseases, and metabolic disorders. LISCure operates primarily in the healthcare and pharmaceutical markets, serving clients that include healthcare providers, research institutions, and pharmaceutical companies. The business model revolves around research and development (R&D) of innovative drug therapies, with revenue generated through partnerships, licensing agreements, and direct sales of their proprietary treatments. LISCure recently completed a seed funding round of USD 5 million to enhance their R&D capabilities, particularly in the area of bacteria-mediated immunotherapy.

Source: Dealroom company data

At a glance

Status
Operational
Employees
6
Open positions
None listed
Dealroom signal
62.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VCOther financing Jan 2025 $41M $164M Undisclosed ↗
SERIES BOther financing Feb 2021 $21M $84M Undisclosed —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

LISCure Biosciences website traffic

Latest recorded traffic for LISCure Biosciences is 1.8K monthly website visits, up 122.2% over the last three months. LISCure Biosciences's team declined 33.3% over the past year.

Latest monthly visits1.8K 3-month web change+122.2% 1-year team growth-33.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

LISCure Biosciences in the Seoul ecosystem

Live from Dealroom

The LISCure Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

  • NHN Investment
  • Shinhan Investment Corporation

Series A1 investor entered at this stage

  • Intron Bio Technologies
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇰🇷 South Korea66.7%
🇺🇸 United States33.3%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about LISCure Biosciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See LISCure Biosciences’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.